Replies to post #40124 on Biotech Values

[daved]

Re RPRX I agree each drug has different characteristics. I'm happy that asoprisnil, which was further along, is no longer a threat. That it got well into P3 b4 serious problems became apparent gives me pause. Ergo my interest in more recent RU 486 data.

Hopefully it won't work for reasons that won't affect proellex. Does anyone know how big a problem the 8% incidence of elevated levels of hepatic enzymes might have on the RU 486 safety profile vis a vis Proellex?

I asked for the royalty and penetration assumptions by Think Equity because it would help evaluate the value of proellex to another company. In earlier models they showed only a 2.8 % market penetration. The home run results and lack of competition from Asoprisnil seem to augur well for Proellex becoming the standard of care, if approved, for 2 indications. Asoprisnil was forecasted to be a $700 mil drug. I'm thinking Proellex could be a billion due to excellent safety (so far) and very robust responses.

Dave